Recently, Zhejiang Procon Pharmaceutical Co., Ltd., a subsidiary of Procon Pharmaceuticals, received exclusive approval for its ephedrine sulfate injection, which is considered to have passed the consistency evaluation. As a blockbuster drug that was exclusively applied for and approved in China, the successful launch of this product not only enriches the company's anesthetic drug product line, but also fills the clinical gap for ephedrine preparations that can be administered intravenously and are suitable for various anesthetic environments, providing a more standardized and reliable new medication option for patients with perioperative hypotension.

Perioperative hypotension is one of the most common complications in clinical anesthesia. According to data from the China Health Statistics Yearbook (2024 Edition), the number of surgeries in my country reached 96.39 million in 2023, with an incidence of hypotension during anesthesia as high as 93%, which is estimated to be nearly 89.64 million cases per year. Clinical demand for efficient and convenient blood pressure management drugs is extremely urgent.

Ephedrine sulfate injection is a classic medication for perioperative blood pressure management in clinical practice. By dual activating α and β receptors, it can rapidly raise blood pressure and stabilize circulation, making it a preferred drug for managing hypotension caused by spinal anesthesia, general anesthesia, etc. This product can be administered directly via intravenous bolus, with rapid onset and stable action, effectively preventing and treating anesthesia-related hypotension. Compared to the commonly used hydrochloride preparations in China, sulfate is the mainstream dosage form internationally. According to IMS data, ephedrine sulfate injection was approved for marketing by the US FDA, and its sales exceeded 130 million yuan in just three years, fully validating the clinical value and safety of this product.

This exclusive approval and passing of the consistency evaluation marks a breakthrough for the company in both quality and clinical value in the field of anesthetic drugs. It fully demonstrates the company's commitment to the development philosophy of "strong scientific and technological research and development" and the core advantages of the entire industrial chain built on the integrated strategy of raw materials and formulation.

In the future, the company will continue to deepen its integrated development path of APIs and formulations, increase investment in R&D and innovation, focus on unmet clinical needs, optimize product pipeline layout and core technology system, steadily consolidate its competitive advantage in the field of essential clinical drugs, and provide the public with more affordable and reliable medicines.

https://bydrug.pharmcube.com/news/detail/9d482c635d8c2789efa41d5ea45a1212